Article
Long-term hepatitis B virus (HBV) response to lamivudine-containing highly active antiretroviral therapy in HIV-HBV co-infected patients in Thailand.
PloS one - 1 Jan 2012
Khamduang Woottichai, Gaudy-Graffin Catherine, Ngo-Giang-Huong Nicole, Jourdain Gonzague, Moreau Alain, Luekamlung Nuananong, Halue Guttiga, Buranawanitchakorn Yuwadee, Kunkongkapan Sura, Buranabanjasatean Sudanee, Lallemant Marc, Sirirungsi Wasna, Goudeau Alain
Abstract excerpt
BACKGROUND: Approximately 4 million of people are co-infected with HIV and Hepatitis B virus (HBV). In resource-limited settings, the majority of HIV-infected patients initiate first-line highly active antiretroviral therapy containing lamivudine (3TC-containing-HAART) and long-term virological response of HBV to lamivudine-containing HAART in co-infected patients is not well known. METHODOLOGY/PRINCIPAL FINDING:...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.